Insider Transactions

What LB PHARMACEUTICALS INC's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

	3 months	12 months
Open-market buys	0	6
Sells	0	0
Total trades	0	11

Shares traded

	3 months	12 months
Acquired	0	7,058,409
Disposed	0	0
Net activity	+0	+7,058,409

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

All Buys Sells

Insider	Relation	Date	Transaction	Shares	Price	Value	Shares held
Vida Ventures Gp III, L.l.c.	10% owner	Sep 12	Open-market buy · P	+332,566	$15.00	+$4.99M	880,214
Vida Ventures Gp III, L.l.c.	10% owner	Sep 12	Derivative Conversion · C	+1,262	—	—	1,262
Vida Ventures Gp III, L.l.c.	10% owner	Sep 12	Derivative Conversion · C	+547,648	—	—	547,648
Vida Ventures Gp III, L.l.c.	10% owner	Sep 12	Open-market buy · P	+767	$15.00	+$11.5K	2,029
Nussbaum Ran	Director	Sep 12	Open-market buy · P	+1,000,000	$15.00	+$15M	1,411,681
Nussbaum Ran	Director	Sep 12	Derivative Conversion · C	+411,681	—	—	411,681
Pontifax Management 4 G.p. (2015) Ltd.	10% owner	Sep 12	Open-market buy · P	+1,000,000	$15.00	+$15M	1,411,681
Pontifax Management 4 G.p. (2015) Ltd.	10% owner	Sep 12	Derivative Conversion · C	+411,681	—	—	411,681
Deep Track Biotechnology Master Fund, Ltd.	10% owner	Sep 12	Open-market buy · P	+666,666	$15.00	+$10M	666,666
Deep Track Biotechnology Master Fund, Ltd.	10% owner	Sep 12	Open-market buy · P	+2,000,000	$15.00	+$30M	2,686,138
Deep Track Biotechnology Master Fund, Ltd.	10% owner	Sep 12	Derivative Conversion · C	+686,138	—	—	686,138

Page 1 of 1 · showing the 11 most recent Sign up free to view all 11 transactions and filter by insider →